Sarepta Therapeutics, Inc. Revenue 2009–2025
Sarepta Therapeutics, Inc. reported $2.20B of revenue for fiscal 2025. That was 15.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +307.0%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $2.20B | +15.6% |
| FY 2024 | $1.90B | +53.0% |
| FY 2023 | $1.24B | +33.3% |
| FY 2022 | $933.01M | +32.9% |
| FY 2021 | $701.89M | +30.0% |
| FY 2020 | $540.10M | +41.8% |
| FY 2019 | $380.83M | +26.5% |
| FY 2018 | $301.03M | +94.7% |
| FY 2017 | $154.58M | +2751.6% |
| FY 2016 | $5.42M | +332.6% |
| FY 2015 | $1.25M | -87.2% |
| FY 2014 | $9.76M | — |
| FY 2013 | $0 | — |
| FY 2012 | $0 | — |
| FY 2011 | $0 | — |
| FY 2010 | $0 | — |
| FY 2009 | $0 | — |
Source: Sarepta Therapeutics, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open SRPT 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Sarepta Therapeutics, Inc. reported $2.20B of revenue for fiscal 2025. That was 15.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +307.0%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Sarepta Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSarepta Therapeutics, Inc. — frequently asked questions
What is Sarepta Therapeutics, Inc.'s revenue?
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $2.20B for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Sarepta Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.